Preferred Label : Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002;
NCIt synonyms : Anti-HER3/MUC1 Bispecific Antibody-drug Conjugate DM002; Anti-HER3/Anti-MUC1 Bispecific ADC DM002; DM002-BLD1102 bsADC; HER3 x MUC1 Bispecific Antibody-drug Conjugate DM002; Anti-HER3/Anti-MUC1 ADC DM002; ADC DM002;
NCIt definition : An antibody-drug conjugate (ADC) composed of a bispecific antibody directed against
the tumor associated antigens (TAAs) human epidermal growth factor receptor 3 (HER3;
ErbB3) and mucin-1 (MUC1) conjugated to BLD1102, which consists of a hydrophilic protease-cleavable
linker and the DNA topoisomerase 1 inhibitor BCPT02, with potential antineoplastic
activity. Upon administration, the antibody moiety of anti-HER3/anti-MUC1 bispecific
ADC DM002 targets and binds to HER3 and MUC1 expressed on tumor cells. Upon binding,
internalization and linker cleavage, BCPT02 is released and inhibits DNA topoisomerase
I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest
and tumor cell apoptosis in HER3- and MUC1-expressing tumor cells. DM002 is also able
to induce a bystander effect on neighboring cells in the tumor environment. This further
inhibits the proliferation of tumor cells. HER3, a member of the epidermal growth
factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed
in tumors. MUC1, a type I transmembrane protein, is overexpressed in a variety of
tumor types. It plays an important role in cancer progression and metastasis.;
Molecule name : DM-002; DM 002;
Origin ID : C217373;
concept_is_in_subset
- has_target
